The Effect of Acupuncture on Sarcopenia and Obesity in Patients With Sarcopenic Obesity.
Sarcopenia
1 other identifier
interventional
28
1 country
1
Brief Summary
Sarcopenia is defined by the European Working Group on Sarcopenia in Older People (EWGSOP) as "a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, carrying a risk of adverse outcomes such as physical disability, fractures, falls, impaired quality of life, and death. Obesity is classified according to the Body Mass Index (BMI), which is calculated by dividing weight in kilograms by the square of height in meters. According to the World Health Organization and most current guidelines for Western societies, obesity is defined as a BMI ≥ 30 kg/m². Sarcopenic obesity was first defined by Baumgartner as the co-occurrence of sarcopenia and obesity, measured using DEXA (10). Sarcopenic obesity is defined as the co-occurrence of high adiposity and sarcopenia; a term originally coined to describe low skeletal muscle mass, strength, and physical function, initially diagnosed in the elderly but present across the entire age spectrum. Combining the effects of both sarcopenia and obesity, sarcopenic obesity has been found to be associated with lower quality of life and greater disability, morbidity, and mortality compared to obesity or sarcopenia alone. Acupuncture is derived from the Latin words for needle (acus) and piercing (punctura). In Western languages, it is written as acupuncture. In traditional Chinese medicine, it is believed that diseases are caused by disturbances in the flow of life energy (Qi) circulating in channels called meridians in the body. Acupuncture aims to correct this disrupted energy flow by inserting needles into specific points along the meridians in the body. Numerous studies have reported that acupuncture is widely used in the treatment of obesity. Current evidence-based reviews have shown that acupuncture is effective in treating obesity. It has been suggested that acupuncture is an effective treatment for simple obesity rather than a placebo effect. The literature contains many studies on acupuncture in the treatment of obesity. However, there are no studies on acupuncture in sarcopenic obesity. Our study aimed to determine the effect of acupuncture on sarcopenia and obesity in patients with sarcopenic obesity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 30, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 20, 2026
CompletedFirst Submitted
Initial submission to the registry
August 21, 2026
CompletedFirst Posted
Study publicly available on registry
September 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
September 25, 2026
CompletedSeptember 25, 2026
September 1, 2026
2.3 years
August 21, 2026
September 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Appendicular skeletal muscle mass
Body composition was assessed using a DEXA scanner (Lunar iDXA; GE Healthcare, 3030 Ohmeda Drive, Madison, WI 53718, USA). Participants' weight, muscle mass and lean mass values were recorded. ASM was calculated as the sum of the bone-free lean mass of the four limbs.
baseline-Week 6-Week 12
weight
The weight was measured with a standardized weight scale.
baseline-week 6-week 12
body mass index
BMI was calculated as weight in kilograms divided by height in meters squared (kg/m²).
baseline-week 6-week 12
Secondary Outcomes (6)
hand grip strength
baseline-week 6-week 12
waist circumference and hip circumference measurement
baseline-week 6-week 12
Sit-Up and Stand-Up Test (from a Chair)
baseline-week 6-week 12
Walking speed of 4 meters
baseline-week 6-week 12
Sarcopenia Quality of Life Scale (SarQoL)
baseline-week 6-week 12
- +1 more secondary outcomes
Study Arms (2)
exercise+diet
ACTIVE COMPARATORThis group will receive a total of 10 sessions per week, 2 days a week consisting of aerobic exercises, resistance exercises, posture and balance exercises, and breathing exercises, as well as a diet program targeting sarcopenic obesity.
acupuncture+exercise+diet
ACTIVE COMPARATORThe second group will receive acupuncture treatment in addition to diet and exercise. Acupuncture treatment will be administered twice a week for a total of 10 sessions, with each session lasting at least 20 minutes. The acupuncture points used in the treatment have been determined based on previous research and are as follows: body acupuncture points ST25, ST36, SP15, LI4, Ren12, Ren6, Ki3, GB34, SP3, SP6, Liv8, SJ-6, Du 20, Yin Tang, Tai Yin; ear acupuncture points are shenmen, large intestine, hunger, and mouth points.
Interventions
This group will receive a total of 10 sessions per week, 2 days a week consisting of aerobic exercises, resistance exercises, posture and balance exercises, and breathing exercises, as well as a diet program targeting sarcopenic obesity.
The second group will receive acupuncture treatment in addition to diet and exercise. Acupuncture treatment will be applied twice a week for a total of 10 sessions, with each session lasting at least 20 minutes. The acupuncture points the investigators will use in the treatment have been determined based on previous research and are as follows: body acupuncture points ST25, ST36, SP15, LI4, Ren12, Ren6, Ki3, GB34, SP3, SP6, Liv8, SJ-6, Du 20, Yin Tang, Tai Yin; ear acupuncture points are shenmen, large intestine, hunger, and mouth points.
Eligibility Criteria
You may qualify if:
- Having the mental and physical capacity to adapt to the work process
- Being between 18-75 years of age
- Being able to ambulate independently or with support
- Having a body mass index (BMI) ≥ 30 kg/m2
You may not qualify if:
- Pregnancy
- Infection
- Pacemaker
- Peripheral circulatory disorder
- Known concomitant malignancy, end-stage organ failure
- Known concomitant central nervous system and/or peripheral nervous system disease
- History of genetic disease
- Coagulopathy
- Having received acupuncture within the last 6 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ayşe Ukbe Baykutlead
- Ankara Bilkent Sehir Hastanesicollaborator
Study Sites (1)
Ankara Bilkent City Hospital
Ankara, çankaya, 06800, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ayşe U Baykut, M.D
Ankara City Hospital Bilkent
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- doctor
Study Record Dates
First Submitted
August 21, 2026
First Posted
September 1, 2026
Study Start
April 30, 2024
Primary Completion
August 20, 2026
Study Completion
September 25, 2026
Last Updated
September 25, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share
I haven't decided yet.